Elucidation of tumor immunoactivation mechanism by cancer microenvironment improving drug

2020 Fiscal Year Final Research Report

• Project/Area Number: 19K18594
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56030:Urology-related
• Research Institution: Osaka City University
• Principal Investigator: Shunji Nishide 大阪市立大学, 大学院医学研究科, 研究員 (10803132)
• Project Period (FY): 2019-04-01 – 2021-03-31
• Keywords: 腫瘍免疫 / 低酸素応答 / マクロファージ / PHD阻害薬

Outline of Final Research Achievements

Macrophages, which are abundant in tumors, promote tumor growth and metastasis in a hypoxic tumor environment, and are a major factor in deteriorating the prognosis of cancer patients. To. Applicants have previously found that PHD inhibitor improve the tumor environment and suppress tumor growth. In this study, based on the results of previous studies, we investigated whether the combined use of PD-1 antibody and CD47 antibody with PHD inhibitors could further suppress tumor growth.
Furthermore, by evaluating genetic changes in macrophages by administering PHD inhibitors, we are analyzing the mechanism of tumor growth suppression by macrophages activated by PHD inhibitors.

Free Research Field

泌尿器科

Academic Significance and Societal Importance of the Research Achievements

本研究により、腫瘍内で貪食が活性化した腫瘍関連マクロファージによって、組織障害性細胞（T細胞やNK細胞など）を活性化する詳細な機序が明らかにすれば、PHD阻害薬によるマクロファージの貪食活性を基盤とした新たな免疫療法が開拓できると考える。